Kornimate/medical-research-clean huggingface dataset:
personal health records and elder medication use quality

Conditions: Adverse Reaction to Drug; Health Behavior; Medication Adherence; Physician-Patient Relations

Summary: purpose: to examine the impact of a personal health record (phr) on medication use safety among older adults. background: online phrs have potential as tools to manage health information. we know little about how to make phrs accessible for older adults and what effects this will have. methods: a phr was designed and pretested with older adults and tested in a six-month randomized controlled trial. after completing mailed baseline questionnaires, eligible computer users aged 65 and over were randomized 3:1 to be given access to a phr (n=802) or serve as a standard care control group (n=273). follow-up questionnaires measured change from baseline medication use, medication reconciliation behaviors, and medication management problems.


Eligibility criteria:
inclusion criteria: * computer use within the past month. * age 65+

Keywords: personal health record medication management patient safety
evaluation of influencing variables in awakening concentration and concentration at body movements of propofol tci (targeted controlled infusion) targeted at the effector site

Conditions: Awareness, Anesthesia

Summary: age has been related to awakening propofol concentration at effector site of tci, but not to the loss of consciousness concentration, neither to the concentration of body movements during surgery, that can be interpreted as a sign of light anesthesia and lead to awareness. this study aims to determinate the incidence and the propofol tci concentration at the effector site, in patients undergoing general anaesthesia without nbds, of any patients body movements, defined as any spontaneous movements (but no reflex movements) during surgery.

target-controlled-infusion (tci), estimating the effect-size concentration (ce) of propofol and its elimination time with a computerized system, provides the anaesthesiologist useful information to guide anaesthesia. although the correlation between propofol at the effector site at loss of consciousness (ce loc) and age is still debated with contrasting results, the correlation between propofol at the effector site at return of consciousness (ce roc) and age is well established, and some authors suggested that, due also for age-related changes in both pharmacokinetics and pharmacodynamics of propofol, its dosage should be reduced in elderly patients. lowering propofol dosage however, can lead to an higher incidence of awareness during general anaesthesia, even if anaesthesia management is guided by consciousness monitors. awareness during anaesthesia has recently been defined not as a binary phenomenon, but as a graded spectra of states and, during general anaesthesia without using neuromuscular blocking drugs (nbds), body movement on the operating table can be taken as an indication of increasing probability of consciousness or 'light' anaesthesia. hence, this study aims to evaluate the impact of age on the concentration at the effector site of propofol-remifentanil anaesthesia administered with tci pump and without nbds. concnetration at the effector site of propofol at the return of consciousness (cep roc) and at any clinical sign of superficialization such as body movements (cep bm) will be considered.

Eligibility criteria:
inclusion criteria: * patients undergoing general anesthesia with propofol and remifentanil delivered with tci infusion pump exclusion criteria: * neurological or psychiatric or cerebrovascular diseases * renal insufficiency * patients unable to understand the information contained in the informed consent form, * patients with intraoperative hemodynamic instability or * patients who was delivered curare agents during anaesthesia
international programs collaborative studies coordinating center

Conditions: Cardiovascular Diseases; Heart Diseases; Lung Diseases

Summary: to continue the work of the collaborative studies coordinating center (cscc) on international studies in cardiopulmonary disease epidemiology. the work was being performed under bilateral agreements that the nhlbi had entered into with russia, the people's republic of china and pakistan. the contract provided nutritional, epidemiologic and biostatistical services in support of these studies.

background: computer processing, biostatistical, and epidemiological services at the collaborative studies coordinating center (cscc) had been funded previously as part of the nhlbi lipid research clinics (lrc) contracts. in fy 1990, contract n01hv08112 was awarded separately from the lrc for the first time and provided services for collaborative studies carried out under nhlbi international bilateral agreements with the ussr, poland, and the people's republic of china. the assistance has provided important contributions to large-scale, international epidemiological studies resulting from bilateral agreements between the united states and other countries. the results of these efforts have provided insights into different disease patterns and trends throughout the world. design narrative: the cscc coordinated data collection and data file transfer, coordinated scientific meetings, visited the collaborating countries, hosted collaborative scientists, and directed data analysis, combining data from all countries.

Eligibility criteria:
no eligibility criteria
muscle function and its biological and physiological determinants in sickle cell disease

Conditions: Sickle Cell Disease

Summary: background : sickle cell patients have profound remodeling of their muscle microcirculation networks with signs of amyotrophy. however, the consequences of these muscle alterations on the functional status of muscles are unknown. in addition, whether the poor physical fitness of sickle cell patients can be attributed, at least partly, to an hypothetical muscle dysfunction has never been tested. purpose : this study will compare the muscle function of legs between sickle cell patients (ss and sc genotypes) and healthy individuals (aa genotype) before, during and after a short localized muscle endurance exercise. abstract : very recently, a study reported large differences between the muscle microcirculation networks of sickle cell patients compared to healthy individuals with decreased capillary density and higher proportion of large capillaries in the former population. in addition, the same study showed signs of amyotrophy in sickle cell patients. however, the muscle function of sickle cell patients has not been investigated and one may suggest that muscle dysfunction could participate in the decrease of physical fitness, in association with the hematological and hemorheological disorders, already reported in this population. the hypothesis is that muscle fatigue during a short localized muscle endurance exercise should be higher in sickle cell patients compared to healthy individuals, due to a greater recruitment of glycolytic fibers and a faster decrease of muscle oxygenation during exercise.


Eligibility criteria:
inclusion criteria: for sickle cell patients : * age ≥ 15 and \< 60 years old, * ss homozygote or sc heterozygote * in clinical steady state (i.e. without vaso-occlusive crisis or recent blood transfusion) * identified by systematic neonatal screening programs, * registered in the french medical social security national program for healthy and non sickle cell subjects: * age ≥ 18 and \< 60 years old * without cardiovascular/respiratory/muscle disease, * registered in the french medical social security national program. exclusion criteria: * other hemoglobinopathies, * stroke or vasculopathy history, * presence of leg ulcers or osteonecrosis, * recent infectious episode (less than 1 month), * chronic transfusion therapy programs, * recent blood transfusion or phlebotomies (less than 3 months), * patients not at steady state, * pregnancy or breast feeding

Keywords: sickle cell disease muscle function hemorheological disorders
thoracic epidurography different position

Conditions: Thoracic Epidural Injection

Summary: it is known that postoperative pain after thoracotomy or lobectomy is very severe, therefore, intraoperative or postoperative pain management using continuous thoracic epidural catheterization is suggested good option to prevent this complication. the spread of local anesthetics is influenced by various factors including volume, location of needle insertion, speed of injection, patient position, age, weight and height. however, there are few studies about the effect of different patient position during thoracic epidural catheterization. this study was designed to evaluate the effect of different patient position affecting thoracic epidurography.

it is known that postoperative pain after thoracotomy or lobectomy is very severe, therefore, intraoperative or postoperative pain management using continuous thoracic epidural catheterization is suggested good option to prevent this complication. the spread of local anesthetics is influenced by various factors including volume, location of needle insertion, speed of injection, patient position, age, weight and height. however, there are few studies about the effect of different patient position during thoracic epidural catheterization. studies of lumbar epidural blockade have shown that lateral position can produce 0-3 segment more to the dependent position compared to the supine position. when the same amount of local anesthetic was injected in supine of sitting position, the most cephalad level of spread was indifferent. recent studies showed that neck flexion demonstrated significant cephalad spread of contrast dye in high thoracic epidural blockade. the purpose of this study was to compare and evaluate the contrast dye spread between different patient position

Eligibility criteria:
inclusion criteria: * lung cancer * liver cancer * stomach cancer * pancreas cancer exclusion criteria: * coagulopathy * infection * previous spine fusion at thoracic level

Keywords: thoracic epidural injection patient position
mk0524a clinical efficacy study (0524a-026)(completed)

Conditions: Hypercholesterolemia

Summary: a study to determine lipid changing effects of mk0524a when compared to niacin extended release (niaspan) and placebo.


Eligibility criteria:
inclusion criteria: * patients must be between the ages of 18 and 70 years * female patients must be pre-menopausal women that have been surgically sterilized, not pregnant and/or not planning to become pregnant exclusion criteria: * patient has a history of peptic ulcer or gout * patient is sensitive to niacin or products containing niacin * patient drinks more than 2 alcoholic drinks per day * patient has certain heart disease, cancer, or is hiv positive
amish : aprovel for management of isolated systolic hypertension

Conditions: Hypertension

Summary: to compare the antihypertensive efficacy and tolerability of irbesartan and irbesartan-hydrochlorothiazide fixed combination therapy with amlodipine and amlodipine plus hydrochlorothiazide in the treatment of isolated systolic hypertension.


Eligibility criteria:
main criteria are listed hereafter: inclusion criteria: * at screening * outpatients * with newly diagnosed and untreated or previously diagnosed, treated and uncontrolled isolated systolic hypertension defined as: * seated systolic blood pressure (sbp) ≥ 160mmhg and \< 220 mmhg \[160-220\[ * and seated diastolic blood pressure (dbp)\< 90 mmhg * at randomization * having completed the 2 to 4-week wash-out/placebo run-in phase * still eligible for blood pressure * seated sbp ≥ 160mmhg and \< 220 mmhg \[160-220\[ * and seated dbp \< 90 mmhg. exclusion criteria (at screening): * participation in a clinical trial within the previous 3 months * patients with a history of irbesartan, amlodipine, or hydrochlorothiazide sensitivity defined as irbesartan, amlodipine, or hydrochlorothiazide discontinuation due to medically significant adverse effects * patients currently or previously treated with angiotensin ii receptor blocker (irbesartan, losartan, candesartan, valsartan, telmisartan, etc.) or dihydropiridine calcium channel blocker (amlodipine, nicardipine, felodipine, nifedipine, etc.) and not responding despite maximum tolerated dose * known or suspected secondary hypertension (e.g., coarctation of aorta, renovascular stenosis, etc.) * known single functional kidney * history of recent myocardial infarction, coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty, or cerebrovascular accident (transient ischaemic attack, stroke) within the last 6 months of study entry * patients with known gastrointestinal, renal, hepatic, endocrine, cardiovascular, pulmonary, immunological or hematological disease which in the opinion of the investigator is active or uncontrolled * patients with significant renal (clearance of creatinine \< 30 ml/mn), hepatic or cardiac insufficiency, or known valvular heart disease * serum potassium \ 5.5 mmol/l (meq/l) * presence of clinically significant ventricular or supraventricular arrhythmias, or second or third degree atrioventricular block, or qtc prolongation (bazett \> 450 msec.) on the ecg * pregnancy or lactation. women of child bearing potential (not post-menopausal) should be using a reliable contraceptive method the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
detection of disease in the upper tract

Conditions: Upper Tract Urinary Carcinoma

Summary: an observational study of cxbladder performance for detection or rule-out of upper tract urothelial cancer. subjects will be prospectively recruited to a single arm observational study to validate the performance characteristics of cxbladder for suspected (utuc) or for patients with a history of utuc and are under surveillance for recurrence of disease.

this is a single arm observational study prospectively recruiting eligible subjects with no apparent uc of the bladder following white light cystoscopy who have positive or suspicious urine cytology or imaging results. participants will undergo all clinical investigations as prescribed by the physician as per standard of care with addition of urine sampling to enable cxbladder and central urine cytology testing. a mid-stream voided urine sample collected at the time of appointment will be used for cxbladder and central urine cytology testing. cxbladder and central cytology results will not be reported to the physician. urine sample testing will occur at pacific edge ltd laboratories (dunedin, new zealand). central urine cytology will be processed by an independent testing laboratory (southern community laboratories, dunedin, new zealand). the remainder of the urine sample will be used for dipstick analysis of specific gravity, leucocytes, nitrites, blood, haemoglobin, and ph. the unused portion of this sample will be used for local cytology and any other analysis as deemed clinically appropriate. central urine cytology results are not available to physicians.

Eligibility criteria:
inclusion criteria: 1. suspected to have utuc following negative cystoscopy but positive or suspicious imaging and/or urine cytology. 2. under surveillance for utuc following a previous confirmed diagnosis of utuc 3. able to provide a voided urine sample of the required 30 ml minimum volume 4. able to give written consent 5. able and willing to comply with study requirement 6. aged 18 years or older exclusion criteria: 1. prior genitourinary manipulation (flexible or rigid cystoscopy / catheterisation, urethral dilation) in the 14 days before urine collection 2. total cystectomy of the bladder with bowel urinary diversion 3. pregnancy

Keywords: observational upper urinary tract carcinoma hematuria
paracetamol treatment in hypertension: effect on blood pressure (path-bp) study

Conditions: Blood Pressure

Summary: the purpose of this study is to examine if chronic paracetamol dosing increases blood pressure in patients with known high blood pressure.

a prospective randomised, double-blind, crossover trial, comparing the effects of paracetamol 1g (500mg x2) four times daily with matched placebo on ambulatory and clinic bp, each given for 14 days, with a 14-day washout period.

Eligibility criteria:
inclusion criteria: * ≥18 years old, men or post-menopausal women (women with no periods for 12 months or more, or those who have had a surgical menopause) * treated hypertensive patients with an average daytime ambulatory blood pressure measurement (abpm) \<150/95mmhg on stable doses of one or more antihypertensive medication (at least one of which should be; an ace inhibitor, angiotensin receptor blocker or diuretic) for 3 months, or untreated hypertensive patients with an average daytime abpm ≥135/85 but \<150/95. exclusion criteria: * history of ischaemic heart disease, cardiac failure, cerebrovascular disease, liver impairment (alt/ast\>50iu/l) or stage 3-5 chronic kidney disease. * history of overdose or suicidal ideation * patients weighing \<55kgs. * patients with chronic pain requiring treatment, with a known allergy to paracetamol, or concomitant use of non-steroidal anti-inflammatories , oral anticoagulants or corticosteroids.

Keywords: blood pressure hypertension paracetamol acetaminophen
quality of life related to different treatment protocols for post-thyroidectomy hypoparathyroidism

Conditions: Hypoparathyroidism Postprocedural; Quality of Life

Summary: this study aims to compare two different protocols commonly used in the management of post thyroidectomy hypoparathyroidism : pth based calcium repletion and empiric repletion. the investigators aim to compare the quality of life associated with these two protocols in a randomized trial.

enrolled patients will be randomized in two treatment groups. in group 1, all patients will receive calcium carbonate and calcitriol in the post-operative period, with standardized weaning. in group 2, patients will be prescribed calcium carbonate and calcitriol only if their post-operative pth dosage is 25% or less of the pre-operative dosage, or if post-operative pth is inferior to 15. the short-form 36 (sf-36) questionnaire (french canadian version) will be used to assess quality of life pre-operatively and at post-op week 1 and 4. symptoms of hypocalcemia and adverse effects of calcium carbonate and calcitriol will be monitored at week 1 and 4.

Eligibility criteria:
inclusion criteria: * total thyroidectomy or completion hemithyroidectomy exclusion criteria: * need for neck dissection * unable to fill in questionnaires (intellectual deficit, severe psychiatric disorder, illiterate, does not speak french or english)
shulman fasciitis prevalence study in alsace

Conditions: Shulman Fasciitis

Summary: shulman fasciitis or eosinophilic fasciitis (ef) is a rare inflammatory disease, usually benign but disabling, described by shulman in 1974. the diagnosis is suggested by the clinic, confirmed by mri and confirmed by histology, there really no published diagnostic criteria validated for this rare disease. the low number of cases reported in the literature reflects the difficulty of studying the epidemiology of this disease, to establish and evaluate therapeutic strategies and to assess prognosis. work on this subject are few. to our knowledge, no study has previously used to estimate the incidence and prevalence of this disease. therefore, the investigators want to determine the prevalence of fes in alsace in 2016 by a study "capture-recapture" using several independent sources of identification of cases in order to have recent epidemiological data and learn more about this disease.


Eligibility criteria:
inclusion criteria: * patients aged over 18 years * patients suffering from fasciitis shulmande and living in alsace at 1 january 2016 exclusion criteria: * refusal to participate in the study

Keywords: shulman fasciitis shulman fasciitis eosinophilic fasciitis inflammatory disease prevalence
galectin role in periodontal disease

Conditions: Gingivitis; Periodontitis

Summary: this study aimed at exploring the effect of nonsurgical periodontal treatment on galectin 1 and 3 gcf levels in patients having gingivitis, periodontitis stage iii compared to periodontally healthy individuals and if galectin-1 and -3 could serve as diagnostic markers and/or therapeutic targets for periodontitis, in addition to revealing their possible role in the periodontal disease. 45 systemically healthy participants were enrolled in this investigation, equally subdivided into three groups of 15 patients each: gingivitis, periodontitis (stage iii) and control group with healthy gingiva. probing depth, clinical attachment level, gingival and plaque index were registered. gcf levels of galectin-1 and -3 were evaluated in all included groups (before and after non-surgical treatment for periodontitis group) using enzyme linked immune-sorbent assay (elisa) kit.


Eligibility criteria:
inclusion criteria: 1. non-smokers from both genders. 2. not suffering from systemic diseases, pregnancy/lactation. 3. not taking contraceptive pills, antibiotics, anti-inflammatory, or immunosuppressive drugs before inclusion in the study by 6 months. 4. patients with only gingivitis or periodontitis stage iii. 5. periodontitis patients who did not receive any professional periodontal treatment in the last 6 months. exclusion criteria: 1. smokers. 2. having systemic diseases, pregnancy/lactation. 3. taking contraceptive pills, antibiotics, anti-inflammatory, or immunosuppressive drugs in the past 6 months. 4. patients having periodontitis any other stage than stage iii. 5. periodontitis patients who receive any professional periodontal treatment in the last 6 months.
pret: patients prone to recurrence after endovascular treatment

Conditions: Intracranial Aneurysm; Subarachnoid Hemorrhage

Summary: the pret study aims at comparing two types of coils used in the endovascular treatment of intracranial aneurysms. the first type made of platinum has been used for more than 15 years. the other, referred to as hydrocoil, containing in addition to platinum a polymer layer that expands when in contact with blood, has been in use since 2002. the hypothesis of the pret study is that the newer hydrocoil will be more effective and yet as safe as the older platinum coil.


Eligibility criteria:
inclusion criteria: * all patients presenting at least one aneurysm 'prone to recurrence after endovascular treatment' (pret), defined for the sake of this study as: * pret-1: one ruptured or unruptured aneurysm, never treated, with a dimension ≥10mm (longest axis, including thrombosed portions of large or giant aneurysms); for ruptured lesions, patients should be in wfns grade i, ii or iii. * pret-2: an aneurysm presenting a major recurrence after previous coiling; and judged by the neurovascular team to require elective treatment. * the anatomy of the lesion is such that endovascular treatment is possible with both types of coils (not necessarily certain or probable) * the endovascular physician is content to use either type of coils (platinum or hydrogel-coated coils) but no other type of coils * patient is 18 or older * life expectancy is more than 2 years exclusion criteria: * presence of other aneurysms requiring treatment during the same session * patients with associated cerebral arteriovenous malformations * when parent vessel occlusion, without simultaneous endosaccular coiling of the aneurysm, is the primary intent of the procedure * any absolute contraindication to endovascular treatment, angiography, or anaesthesia such as severe allergies to contrast or medications

Keywords: large aneurysm recurrence hydrocoil